EP3481839B1 - Procédé de purification de méthylcobalamine - Google Patents

Procédé de purification de méthylcobalamine Download PDF

Info

Publication number
EP3481839B1
EP3481839B1 EP17714232.0A EP17714232A EP3481839B1 EP 3481839 B1 EP3481839 B1 EP 3481839B1 EP 17714232 A EP17714232 A EP 17714232A EP 3481839 B1 EP3481839 B1 EP 3481839B1
Authority
EP
European Patent Office
Prior art keywords
methylcobalamin
iron
resin
process according
cyanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17714232.0A
Other languages
German (de)
English (en)
Other versions
EP3481839A1 (fr
EP3481839C0 (fr
Inventor
Juan Sallares Rosell
Francisco Marquillas Olondriz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healthtech Bio Actives SLU
Original Assignee
Healthtech Bio Actives SLU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healthtech Bio Actives SLU filed Critical Healthtech Bio Actives SLU
Publication of EP3481839A1 publication Critical patent/EP3481839A1/fr
Application granted granted Critical
Publication of EP3481839B1 publication Critical patent/EP3481839B1/fr
Publication of EP3481839C0 publication Critical patent/EP3481839C0/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification

Definitions

  • the present invention relates to a process for the purification of methylcobalamin, which is one of the coenzyme forms of vitamin B 12 .
  • Cobalamins are a group of closely related and interconvertible cobalt coordination compounds, which are usually collectively known as vitamin B 12 .
  • Cobalamins belong to the family of corrinoids, which share a planar tetrapyrrolic ring (corrin ring) containing a central cobalt atom, which may assume an oxidation state of (I), (II) or (III). Additionally, cobalamins possess an upper (beta) and a lower (alpha) axial ligands, as represented in the following structure:
  • the lower ligand (alpha) is the dimethylbenzimidazole group of a nucleotide, which is connected to the corrin ring through an amide bond.
  • the beta ligand (R) may be a cyano-, hydroxo-, methyl- or 5'-deoxyadenosyl- group, giving rise, respectively, to cyanocobalamin, hydroxocobalamin, methylcobalamin, and 5'-deoxyadenosylcobalamin.
  • vitamin B 12 refers specifically to cyanocobalamin, i.e., when R is the cyano group (CN).
  • methylcobalamin and 5'-deoxyadenosylcobalamin are the active forms that function as coenzymes for metabolic reactions in the organism, namely in those reactions catalysed by the enzymes methionine synthase and methylmalonyl-CoA mutase, which are related, for example, to red blood cell formation, neurological function, and DNA synthesis. Consequently, vitamin B 12 deficiency is associated with several pathologies, such as megaloblastic anaemia, fatigue, weakness, constipation, loss of appetite, weight loss, and neurological disorders. In such deficiency states, the administration of cobalamins is indicated.
  • Methylcobalamin in particular, is successfully used in therapy for treating several disorders associated to vitamin B 12 deficiency, for example, for treating peripheral neuropathy or megaloblastic anaemia.
  • Methylcobalamin is commonly obtained from cyanocobalamin, by means of a reductive methylation process, involving the treatment of cyanocobalamin with a reducing agent and with a methylating agent.
  • a reductive methylation process involving the treatment of cyanocobalamin with a reducing agent and with a methylating agent.
  • the cyanide anions which are released from cyanocobalamin during the reduction reaction, tend to bond again to the reduced form of cobalamin, known as cob(I)alamin or vitamin B 12S , competing with the methylating agent and, thus, lowering the overall reaction yield of the process.
  • this reaction can be advantageously performed in the presence of an agent able to act as cyanide scavenger, i.e., by complexing the cyanide anions present in the reaction media and thus avoiding any interference with the methylation process.
  • an agent able to act as cyanide scavenger i.e., by complexing the cyanide anions present in the reaction media and thus avoiding any interference with the methylation process.
  • metallic salts particularly, iron (II) salts.
  • GB 1419933 discloses the preparation of methylcobalamin by reductive methylation of cyanocobalamin using monomethyl oxalate and zinc as methylating agents and using cobalt chloride as a catalyst.
  • Methylcobalamin was dissolved in an acetone aqueous solution and purified using cation and anion exchange resins were used. After purification, acetone was added and the solution was left to crystallise to yield methylcobalamin.
  • the European patent application EP1236737-A1 discloses the preparation of methylcobalamin by reductive methylation of cyanocobalamin using trimethylsulfoxonium or trimethylsulfonium halide salts as methylating agents and using iron (II) sulphate heptahydrate and/or cobalt (II) chloride hexahydrate as cyanide scavenging agents.
  • iron salts which are efficient for improving the performance of the reductive methylation process, may lead to iron residues in the final pharmaceutical substance, and consequently in the final drug product.
  • the object of the present invention is a process for the purification of methylcobalamin.
  • the object of the present invention is a process for the purification of methylcobalamin from mixtures with iron cyanide anions characterized in that it comprises contacting a solution comprising methylcobalamin and iron cyanide anions with a strongly basic anion exchange resin.
  • the authors of the present invention have developed a new process for the purification of methylcobalamin based on the treatment with a strongly basic anion exchange resin, which, surprisingly, allows the efficient removal of traces of iron cyanide anions present in methylcobalamin solutions using a simple process which can be easily industrially implemented to provide methylcobalamin with a reduced iron content.
  • This process can advantageously be used for removing iron cyanide impurities from methylcobalamin obtained by reductive methylation of cyanocobalamin wherein iron (II) salts are used as cyanide scavengers, thus providing methylcobalamin with a reduced iron content.
  • An anion exchange resin as is well known in the art, is an insoluble polymeric matrix containing anions which are able to be exchanged with other anions in solutions which come in contact with them.
  • a strongly basic anion exchange resin is a particular type of anion exchange resin wherein the anion which is exchanged is the counterion of a quaternary ammonium group which is bound to the polymeric matrix of the resin, typically a trialkylammonium group such as trimethylammonium, or a dialkyl 2-hydroxyethyl ammonium group.
  • the resin has trialkylammonium functional groups, more preferably trimethylammonium groups.
  • the counterion which is exchanged, is generally a chloride or a hydroxide anion.
  • the counterion is a chloride anion.
  • the polymeric matrix of the resin can be a crosslinked polystyrene-divinylbenzene polymer, i.e., prepared from styrene and divinylbenzene as cross-linking agent; or can be a crosslinked acrylic polymer, prepared from acrylic acid, methacrylic acid, or esters of acrylic or methacrylic acid, e.g. methyl, ethyl, or propyl esters, crosslinked with e.g. divinylbenzene, ethyleneglycol dimethacrylate, ethyleneglycol divinyl ether, or diethyleneglycol divinyl ether.
  • the resin is selected from a crosslinked polystyrene-divinylbenzene resin and a crosslinked acrylic-divinylbenzene resin.
  • the resin is a crosslinked acrylic-divinylbenzene resin.
  • the resins are generally available in form of beads. According to its porosity, the resin can be microporous (gel-type) or macroporous (macroreticular). Preferably, the resin has macroreticular structure.
  • the strongly basic anion exchange resin is a resin having trialkylammonium functional groups and interchanging chloride anions. More preferably, the resin is a crosslinked acrylic-divinylbenzene resin having macroreticular structure.
  • a number of strongly basic anion exchange resins suitable to be used in the process of the present invention are commercially available, for example, Amberlite ® IRA458 RF Cl, Amberlite ® IRA900 Cl, Amberlite ® IRA958 Cl; Diaion ® SA10A(CI), Diaion ® HPA25(CI), Dowex ® Marathon A, Dowex ® Marathon MSA, Lewatit ® MonoPlus MP500, Lewatit ® MonoPlus MP800, or the strongly basic anion exchange resins from the company Purolite, for example of the Purolite ® A200 or Purolite ® A500 series; among others.
  • Amberlite ® IRA958 CI is particularly preferred. It is a macroreticular, strongly basic anion exchange resin having quaternary ammonium functionality in a crosslinked acrylic polymer matrix and interchanging chloride anions.
  • the purification process according to the present invention can advantageously be used for removing iron cyanide impurities from methylcobalamin obtained by reductive methylation of cyanocobalamin wherein iron (II) salts are used as cyanide scavengers.
  • This purification process is particularly useful for removing residual amounts, namely trace amounts, of iron cyanide anions which still remain as impurities of methylcobalamin, even after having removed a large proportion of the iron cyanide formed in the process by filtering off insoluble iron cyanide salts.
  • the amount of residual iron cyanide impurities contained in methylcobalamin, which are to be removed with the process of the current invention by treatment with the resin is generally equivalent to less than 6000 ppm of iron, preferably less than 5000 ppm of iron, more preferably less than 4000 ppm of iron, and still more preferably less than 1600 ppm.
  • the process of contacting the solution comprising methylcobalamin and iron cyanide anions with the strongly basic anion exchange resin is preferably performed by passing the solution through an effective amount of the resin.
  • a column is filled with an adequate amount of the resin and the solution comprising methylcobalamin and iron cyanide anions is passed through it, either in down-flow or in upper-flow, and the resulting solution is subsequently collected.
  • the solution is passed in upper-flow.
  • the solution is passed through the resin over a certain period of time, generally comprised between 2 and 6 hours, and more preferably comprised between 3 and 4 hours.
  • the strongly basic anion exchange resin is used in a weight ratio resin:methylcobalamin generally comprised between 0.1:1 and 2:1, and more preferably comprised between 0.3:1 and 1:1.
  • the weight ratio resin:methylcobalamin is approximately 0.5:1.
  • an amount of solvent alone is subsequently passed through the resin to collect the methylcobalamin that can remain within the resin.
  • the iron cyanide anions present in the solution are retained by the resin, while the counterion of the resin, typically the chloride anion, is in turn released.
  • iron cyanide anions are meant to be anionic iron (II) or iron (III) complexes with cyanide.
  • iron cyanide anions typically, among the iron cyanide anions are the ferrocyanide anions, also known as hexacyanoferrate (II) anions ([Fe(CN) 6 ] 4- ) and the ferricyanide anions, also known as hexacyanoferrate (III) anions ([Fe(CN) 6 ] 3- ).
  • the iron cyanide anions present as impurities of methylcobalamin may be a mixture of different iron cyanide complexes.
  • the anion interchange that takes place between the anion exchange resin and the ferrocyanide anions can be represented as follows:
  • Example 3 the methylcobalamin obtained by reductive methylation of cyanocobalamin using iron salts as cyanide-scavengers could be effectively separated from iron cyanide impurities using the method of the present invention, thus obtaining methylcobalamin having less than 130 ppm of iron, namely 71 ppm or even less than 30 ppm, whereas when the same process was performed without using a strongly basic anion exchange resin, the level of iron in methylcobalamin was much higher, 494 or 1594 ppm.
  • the anion exchange resin Upon usage, the anion exchange resin progressively loses its capacity of anion exchanging, as more iron cyanide anions get retained into it.
  • the exhausted resin can be regenerated with an aqueous solution of a salt of the resin counterion, preferably an aqueous solution of a chloride salt, more preferably an aqueous solution of sodium chloride.
  • the solvent used for performing the purification process, in which methylcobalamin and the iron cyanide anions are dissolved can be water or a mixture of water with a water-miscible organic co-solvent.
  • Suitable organic co-solvents include, but are not limited to, alcohols such as methanol, ethanol, n-propanol, isopropanol, or tert-butanol; ketones such as acetone or 2-butanone; ethers such as 1,4-dioxane, tetrahydrofuran, dimethoxyethane or diglyme; and mixtures thereof.
  • the solvent is a mixture of water and a water-miscible organic co-solvent, preferably a mixture of water and a water-miscible co-solvent selected from an alcohol, a ketone, and mixtures thereof; more preferably the solvent is a mixture of water and a water-miscible ketone, and still more preferably is a mixture of water and acetone.
  • the volume proportion water:organic solvent is generally comprised between 1.8:1 and 1:1.5, preferably comprised between 1.5:1 and 1:1.2, more preferably comprised between 1.1:1 and 1:1.1.
  • the solvent is a mixture of water and acetone in approximately 1:1 volume proportion.
  • the solution containing methylcobalamin and the iron cyanide impurities which is contacted with the anion exchange resin comprises methylcobalamin in a concentration generally comprised between 30-150 g/L, preferably between 40-100 g/L, and more preferably comprised between 50-75 g/L.
  • methylcobalamin can be isolated by crystallizing or precipitating it from the solution, generally adding a ketone solvent to the solution, preferably adding acetone to the solution.
  • the solution which is subjected to the purification process is prepared by treating the crude methylcobalamin comprising iron cyanide impurities with the solvent and heating to a temperature comprised between 30° C and 60° C, preferably between 40° C and 50° C, and more preferably at approximately 45° C, during a period of time generally comprised between 15 and 60 minutes.
  • the suspension thus obtained is generally filtered to remove the insoluble impurities, for example, insoluble iron cyanide salts, and the filtered solution, still containing residual iron cyanide anions, is then contacted with the strongly basic anion exchange resin, according to the process of the invention.
  • the purification of methylcobalamin comprises the following steps:
  • the methylcobalamin obtained after performing the process of the invention has a reduced iron content, namely, the amount of iron is less than 130 ppm, preferably less than 90 ppm, still more preferably less than 80 ppm, and still more preferably less than 70 ppm of iron.
  • the determination of the iron amount can be performed, for example, by inductively coupled plasma optical emission spectrometry (ICP/OES).
  • ICP/OES inductively coupled plasma optical emission spectrometry
  • Another aspect of the present invention is the use of a strongly basic anion exchange resin for removing iron cyanide anions from methylcobalamin.
  • the methylcobalamin containing iron cyanide impurities which is susceptible to be purified with the process of the invention, is typically the result of a reductive methylation reaction of cyanocobalamin, performed in the presence of iron (II) salts and optionally iron (III) salts as cyanide scavengers.
  • the reductive methylation of cyanocobalamin is typically carried out by treatment of cyanocobalamin with a reducing agent and a methylating agent.
  • cyanocobalamin ( CAS number 68-19-9 ) is commercially available from several sources.
  • the reducing agent can be any agent capable of reducing the cobalt of cyanocobalamins from Co(lll) to Co(I).
  • Suitable reducing agents are, for example, alkaline metal borohydrides.
  • a preferred reducing agent is sodium borohydride.
  • the amount of reducing agent is not particularly limited, but is generally comprised between 5 and 30 equivalents, preferably between 10 and 20 equivalents to cyanocobalamin.
  • methylating agent can be employed, for example, trimethylsulfonium bromide, trimethylsulfonium chloride, trimethylsulfonium methylsulphate, trimethylsulfoxonium chloride, trimethylsulfoxonium iodide, trimethylsulfoxonium bromide, dimethyl carbonate, dimethyl sulphate, tetramethylammonium chloride or methyl iodide.
  • the methylating agent is selected from the group consisting of trimethylsulfonium bromide, trimethylsulfonium chloride, trimethylsulfoxonium chloride, trimethylsulfoxonium iodide, trimethylsulfoxonium bromide and dimethyl carbonate.
  • the amount of methylating agent employed is generally comprised between 1 and 10 equivalents, preferably between 2 and 5 equivalents to cyanocobalamin.
  • the reductive methylation reaction is performed in aqueous media, optionally in combination with a water-miscible organic co-solvent.
  • suitable co-solvents are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, or tert- butanol; ketones such as acetone or 2-butanone; ethers such as 1,4-dioxane, tetrahydrofuran, dimethoxyethane or diglyme; amides such as dimethylformamide, or dimethylacetamide; and mixtures thereof.
  • co-solvents preferably alcohols or ketones are used.
  • the reaction is preferably carried out at slightly basic pH, e.g. 7.5-8.5, and at a temperature in the range 5-60° C, preferably in the range 20-40° C.
  • An iron (II) salt is added to the reaction as cyanide scavenger, for example, iron (II) sulphate, iron (II) chloride, or ammonium iron (II) sulphate (Mohr's salt).
  • the cyanide ions released in the reduction reaction are complexed by the iron (II) cation to form anionic iron (II) cyanide complexes, for example, the ferrocyanide complex [Fe(CN) 6 ] 4- , thus avoiding that they interfere with the methylation process.
  • the iron (II) salt is employed in an amount generally comprised between 0.5 and 1.5 equivalents to cyanocobalamin, and preferably approximately 1 equivalent of iron (II) salt to cyanocobalamin is employed.
  • an iron (III) salt is also added, typically to form insoluble salts with the ferrocyanide anion, thus allowing their simple removal by filtration.
  • the reaction is generally performed by dissolving cyanocobalamin, an iron (II) salt, and optionally an iron (III) salt, and adding, sequentially or simultaneously, the reducing agent and the methylating agent.
  • Cyanocobalamin and methylcobalamin solutions are known to be susceptible photo-oxidation, therefore, the reductive methylation process is preferably performed under inert atmosphere, for example under flow of an inert gas such as nitrogen, and in absence of light, under red-light illumination.
  • inert atmosphere for example under flow of an inert gas such as nitrogen, and in absence of light, under red-light illumination.
  • methylcobalamin is generally precipitated from the reaction mixture, by cooling the reaction media, typically also adding further organic solvent, and filtering the crude methylcobalamin.
  • the crude methylcobalamin thus obtained contains salts containing iron cyanide anions, and can be then purified using the process of the present invention, so it is made into a solution, by treating it with a suitable solvent, as disclosed above.
  • the content of iron impurity in the methylcobalamin was less than 30 ppm, determined by inductively coupled plasma/optical emission spectrometry (ICP/OES).
  • a second batch (batch B) and third batch (batch C) of methylcobalamin were prepared according to the same processes a) and b) disclosed above. Methylcobalamin was obtained in a yield of 84.4% and 87.9%, respectively, and the iron content was 71 ppm and less than 30 ppm, respectively.
  • the content of iron impurity in the methylcobalamin was 494 ppm, determined by inductively coupled plasma/optical emission spectrometry (ICP/OES).
  • a second batch (batch 2) of methylcobalamin was prepared according to the same process disclosed above. Methylcobalamin was obtained in a yield of 86.7%, and the iron content was 1594 ppm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

  1. Procédé de purification de méthylcobalamine (I)
    Figure imgb0005
     à partir de mélanges avec des anions cyanure de fer, qui sont des complexes de fer (II) ou de fer (III) avec du cyanure, caractérisé en ce qu'il comprend la mise en contact d'une solution comprenant de la méthylcobalamine et des anions cyanure de fer avec une résine échangeuse d'anions fortement basique, caractérisé en ce que la méthylcobalamine qui est purifiée est obtenue par méthylation réductrice de cyanocobalamine en présence de sels de fer (II) et facultativement de sels de fer (III) comme piégeurs de cyanure.
  2. Procédé selon la revendication 1, caractérisé en ce que la résine échangeuse d'anions fortement basique a des groupes fonctionnels trialkyl ammonium et échange des anions chlorure.
  3. Procédé selon la revendication 1 ou 2, caractérisé en ce que la résine est choisie parmi une résine de type polystyrène-divinylbenzène réticulée et une résine de type acrylique-divinylbenzène réticulée.
  4. Procédé selon l'une quelconque des revendications 1 à 3, caractérisé en ce que la résine est une résine de type acrylique-divinylbenzène réticulée à structure macroréticulaire.
  5. Procédé selon l'une quelconque des revendications 1 à 4, caractérisé en ce que le procédé de mise en contact de la solution comprenant de la méthylcobalamine et des anions cyanure de fer avec la résine échangeuse d'anions fortement basique est réalisé en faisant passer la solution à travers une quantité efficace de la résine sur une durée de temps comprise entre 2 et 6 heures.
  6. Procédé selon l'une quelconque des revendications 1 à 5, caractérisé en ce que le rapport de poids résine: méthylcobalamine est compris entre 0,1 : 1 et 2 : 1.
  7. Procédé selon la revendication 6, caractérisé en ce que le rapport de poids résine: méthylcobalamine est d'environ 0,5 : 1.
  8. Procédé selon l'une quelconque des revendications 1 à 7, caractérisé en ce que le solvant utilisé dans la solution est choisi parmi l'eau et un mélange d'eau avec un co-solvant organique miscible à l'eau.
  9. Procédé selon la revendication 8, caractérisé en ce que le solvant est un mélange d'eau et un co-solvant organique miscible à l'eau.
  10. Procédé selon la revendication 9, caractérisé en ce que le solvant est un mélange d'eau et acétone.
  11. Procédé selon les revendications 9 ou 10, caractérisé en ce que le rapport volumique eau: co-solvant organique est compris entre 1,8 : 1 et 1 : 1,5.
  12. Procédé selon l'une quelconque des revendications 1 à 11 , caractérisé en ce que la méthylcobalamine est cristallisée à partir de la solution recueillie après le traitement avec la résine.
  13. Procédé selon l'une quelconque des revendications 1 à 12, caractérisé en ce que la solution qui est soumise au procédé de purification est préparée en traitant de la méthylcobalamine comprenant des impuretés de cyanure de fer avec le solvant, en chauffant à une température comprise entre 30°C et 60°C, et filtrant pour enlever les impuretés insolubles.
  14. Procédé selon l'une quelconque des revendications 1 à 13, caractérisé en ce que la méthylcobalamine obtenue a une teneur en fer de moins de 130 ppm.
EP17714232.0A 2016-07-08 2017-03-30 Procédé de purification de méthylcobalamine Active EP3481839B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16178560 2016-07-08
PCT/EP2017/057506 WO2018007035A1 (fr) 2016-07-08 2017-03-30 Procédé de purification de méthylcobalamine

Publications (3)

Publication Number Publication Date
EP3481839A1 EP3481839A1 (fr) 2019-05-15
EP3481839B1 true EP3481839B1 (fr) 2023-06-07
EP3481839C0 EP3481839C0 (fr) 2023-06-07

Family

ID=56497551

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17714232.0A Active EP3481839B1 (fr) 2016-07-08 2017-03-30 Procédé de purification de méthylcobalamine

Country Status (7)

Country Link
US (1) US11059851B2 (fr)
EP (1) EP3481839B1 (fr)
JP (1) JP6867409B2 (fr)
ES (1) ES2952837T3 (fr)
HU (1) HUE063127T2 (fr)
PL (1) PL3481839T3 (fr)
WO (1) WO2018007035A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108546278A (zh) * 2018-03-17 2018-09-18 山东辰龙药业有限公司 甲钴胺的精制方法
CN108948116A (zh) * 2018-08-30 2018-12-07 上海应用技术大学 一种甲钴胺的绿色合成工艺
WO2022087656A1 (fr) * 2020-10-27 2022-05-05 Commonwealth Scientific And Industrial Research Organisation Procédé d'élimination du cyanure d'un fluide aqueux contenant du cyanure
CN113959805B (zh) * 2021-10-25 2024-06-21 淄博高新技术产业开发区生物医药研究院 甲钴胺原料药中氯化钴杂质的分析检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4538059B1 (fr) 1967-07-27 1970-12-02
BE759614A (fr) 1969-12-01 1971-06-01 Glaxo Lab Ltd Elimination d'ions cyanure de solutions de corrinoides
US3928320A (en) * 1971-11-10 1975-12-23 Jean Boige Process for the preparation of methylcobalamine
NO742545L (fr) * 1973-08-08 1975-03-10 Opochimie L
KR100694688B1 (ko) 1999-12-09 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 메틸코발라민의 제조 방법
EP1394174B1 (fr) * 2001-06-05 2015-11-11 Eisai R&D Management Co., Ltd. Procede de production de methylcobalamine

Also Published As

Publication number Publication date
US20200308217A1 (en) 2020-10-01
HUE063127T2 (hu) 2024-01-28
ES2952837T3 (es) 2023-11-06
US11059851B2 (en) 2021-07-13
EP3481839A1 (fr) 2019-05-15
PL3481839T3 (pl) 2023-10-02
JP2019521962A (ja) 2019-08-08
EP3481839C0 (fr) 2023-06-07
JP6867409B2 (ja) 2021-04-28
WO2018007035A1 (fr) 2018-01-11

Similar Documents

Publication Publication Date Title
EP3481839B1 (fr) Procédé de purification de méthylcobalamine
EP0625523B1 (fr) procédé pour préparer un complexe cis-oxalato (trans-L-1,2-cyclohexanediamine) Pt(II) ayant une purété optique élevée
EP2504298B1 (fr) Préparation et purification d'iodixanol
JP3948958B2 (ja) メチルコバラミンの製造法
US4112044A (en) Chromatographic separation of uranium isotopes
JP2010229017A (ja) 高純度パラタングステン酸アンモニウムの製造方法
JP5833795B2 (ja) ホスファプラチン化合物の合成方法および精製方法ならびに該化合物の使用
JP2010022886A (ja) テトラフルオロホウ酸イオンの除去方法
JP2001064249A (ja) アルカンスルホン酸の精製
WO2007104442A2 (fr) Procédé de préparation d'un précurseur de la vitamine b1
CN111233689B (zh) 13c美沙西汀的纯化方法及制备方法
CN107805267B (zh) 一种甲钴胺及其衍生物的纯化方法
EP1874290A1 (fr) Procede de realisation d'une preparation a base d'oxalyplatine
EP3374318B1 (fr) Procédé utilisant des résines d'échange d'ions pour le traitement d'eaux usées émanant de production d'acide téréphtalique purifié
US20080128357A1 (en) Separation of platinum group metals
US3928320A (en) Process for the preparation of methylcobalamine
EP3546472B1 (fr) Procédé de purification de p1, p4-di (uridine 5'-)tétraphosphate
JPH08143590A (ja) 高純度メチルコバラミンの製造方法
JP4089320B2 (ja) 塩基性陰イオン交換樹脂の精製方法
CN118812574A (zh) 一种抗癌药Apitolisib中间体的精制工艺
US2709669A (en) Process for separating vitamin b12 active substances from contaminants
EP2998275B1 (fr) Procédé pour la préparation et/ou purification de chlorure de ruthénium (III)
JP3835487B2 (ja) ロジウムの精製方法
JP3493778B2 (ja) ロジウムの精製及び回収方法
CN112094274A (zh) 一种改进的托法替布合成方法及杂质制备方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HEALTHTECH BIO ACTIVES, S.L.U.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220310

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

INTC Intention to grant announced (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HEALTHTECH BIO ACTIVES, S.L.U.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220916

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1574770

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230615

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017069485

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20230607

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230612

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 42084

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230907

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2952837

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231106

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230401428

Country of ref document: GR

Effective date: 20231010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E063127

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017069485

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240327

Year of fee payment: 8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240327

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240306

Year of fee payment: 8

Ref country code: HU

Payment date: 20240313

Year of fee payment: 8

Ref country code: CZ

Payment date: 20240306

Year of fee payment: 8

Ref country code: GB

Payment date: 20240327

Year of fee payment: 8

Ref country code: SK

Payment date: 20240304

Year of fee payment: 8

U20 Renewal fee paid [unitary effect]

Year of fee payment: 8

Effective date: 20240327

26N No opposition filed

Effective date: 20240308

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240308

Year of fee payment: 8

Ref country code: PL

Payment date: 20240305

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240402

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240401

Year of fee payment: 8